CSI Market
Sign In | Register

Seelos Therapeutics inc (SEEL) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access SEEL quarterly Cash Flow →
Looking at cash flow data from Seelos Therapeutics inc through Dec 31 2019 provides insight into Dec 31 2023's financial flexibility across reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2023)
12 Months 		(Dec 31 2022) (Dec 31 2021) (Dec 31 2020) (Dec 31 2019)
Operating Activities
Income-37.88
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation3.99
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-18.00
Goodwill And Intangible Asset Impairment-
Noncash Interest Expense Income Net-
Non Cash Compensation And Related Expenses-
Increase Decreasein Deferred Rental Income and Other Noncurrent Assets-
Deconsolidation Gain Or Loss Amount-
Increase Decrease In Short Term Liability Arising From Deconsolidation Of Subsidiaries-
Increase Decreasein Deferred Revenue Short Term-
Gain Losseson Extinguishment of Debt Non Cash Operating-
Gain Loss In Fair Value Of Convertible Notes-
Change In Fair Value Of Convertible Notes Payable2.05
Gain Loss On Forgiveness Of Note Payable-
Research And Development Expenses-
Operating Lease Right Of Use Asset Amortization Expense0.06
Net Loss On Extinguishment Of Convertible Debt9.15
Increase Decrease In Operating Lease Liability-0.06
Increase Decrease In Licenses Payable-1.00
Income taxes0.00
Losses/ -gains on Investments net0.00
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable12.78
Increase (Decrease) in Accrued Liabilities-4.22
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets5.69
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities3.54
Discontinued operations0.00
Net Cash flow from Operating Activities-23.91
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Cash Paid For Acquired Businesses-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire in Process Research and Development0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments-7.64
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock-1.03
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Payments For Sale Of Subsidiary Stock-
Gain Loss On Debt Extinguishment Notes Net-
Proceeds From Issuance Of Convertible Notes-
Proceeds From Issuance Of Common Stock In Atthemarket Offering-
Proceeds From Issuance Of Common Stock Net Of Issuance Costs-
Proceeds From Issuance Of Common Stock And Convertible Notes Payable-
Proceeds From Issuance Of Common Stock And Warrants20.05
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities11.38
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-23.91
Total Cash Flow-12.54
4 historic quarters locked

Sign in to unlock the full Seelos Therapeutics inc cash flow history.

Sign In Create Free Account

About Seelos Therapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001410578-24-000140

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License